NTRA · Company research
Natera, Inc. Common Stock (NTRA): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
28records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Should You Invest in the First Trust Health Care AlphaDEX ETF (FXH)? | FXH is a passively managed healthcare ETF launched in 2007 with $1.13 billion in assets. It tracks the StrataQuant Health Care Index with a 0.61% expense ratio and 0.56% dividend yield. The fund has gained 16.87% year-to-date and 20.02% over the past year, with a medium risk profile (beta 0.72). It holds 74 healthcare companies with top holdings including Natera, Guardant Health, and Universal Health Services. FXH received a Zacks ETF Rank of 3 (Hold). | View source ↗ | Zacks Investment Research | Oct 19, 2026 | bullish | 0.333 | 1 |
| Under a preset plan, Natera (NTRA)'s chairman sells 50,000 shares; he also exercises options. - Stock Titan | Under a preset plan, Natera (NTRA)'s chairman sells 50,000 shares; he also exercises options. Stock Titan | View source ↗ | Stock Titan | Oct 17, 2026 | neutral | 0 | 0.6 |
| These Two Biotech Stocks Hit Fresh 52-Week Highs Today – NTRA Clocks Best Day In Nearly 20 Months - Stocktwits | These Two Biotech Stocks Hit Fresh 52-Week Highs Today – NTRA Clocks Best Day In Nearly 20 Months Stocktwits | View source ↗ | Stocktwits | Oct 16, 2026 | neutral | 0 | 0.6 |
| Does FDA Breakthrough Status Change The Bull Case For Natera Stock (NTRA)? - Simply Wall Street | Does FDA Breakthrough Status Change The Bull Case For Natera Stock (NTRA)? Simply Wall Street | View source ↗ | Simply Wall Street | Oct 15, 2026 | neutral | 0 | 0.6 |
| TIME’s 2026 inventions list includes a cancer test Natera says detects recurrence up to 2 years before imaging. - Stock Titan | TIME’s 2026 inventions list includes a cancer test Natera says detects recurrence up to 2 years before imaging. Stock Titan | View source ↗ | Stock Titan | Oct 15, 2026 | neutral | 0 | 0.6 |
| Saudi Arabia Non-Invasive Prenatal Testing Market 2026-2034: Executive Report | NGS Adoption and Healthcare Investment Drive 13.35% CAGR Toward US$162.16 Million | Saudi Arabia's Non-Invasive Prenatal Testing (NIPT) market is projected to grow from US$52.50 million in 2025 to US$162.16 million by 2034, driven by a 13.35% CAGR. Growth is fueled by advances in next-generation sequencing, rising maternal age, increased healthcare investment, and expanding genetic testing capacity. Key players include Eurofins Scientific, Roche, Invitae, Illumina, Natera, Centogene, and Qiagen, with Riyadh and Jeddah leading regional adoption. | View source ↗ | GlobeNewswire Inc. | Oct 15, 2026 | bullish | 1 | 1 |
| Saudi Arabia Non-Invasive Prenatal Testing Market 2026-2034: Executive Report | NGS Adoption and Healthcare Investment Drive 13.35% CAGR Toward US$162.16 Million | Saudi Arabia's Non-Invasive Prenatal Testing (NIPT) market is projected to grow from US$52.50 million in 2025 to US$162.16 million by 2034, driven by a 13.35% CAGR. Growth is fueled by advances in next-generation sequencing, rising maternal age, increased healthcare investment, and expanding genetic testing capacity. Key players include Eurofins Scientific, Roche, Invitae, Illumina, Natera, Centogene, and Qiagen, with Riyadh and Jeddah leading regional adoption. | View source ↗ | GlobeNewswire Inc. | Oct 15, 2026 | bullish | 1 | 1 |
| Saudi Arabia Non-Invasive Prenatal Testing Market 2026-2034: Executive Report | NGS Adoption and Healthcare Investment Drive 13.35% CAGR Toward US$162.16 Million | Saudi Arabia's Non-Invasive Prenatal Testing (NIPT) market is projected to grow from US$52.50 million in 2025 to US$162.16 million by 2034, driven by a 13.35% CAGR. Growth is fueled by advances in next-generation sequencing, rising maternal age, increased healthcare investment, and expanding genetic testing capacity. Key players include Eurofins Scientific, Roche, Invitae, Illumina, Natera, Centogene, and Qiagen, with Riyadh and Jeddah leading regional adoption. | View source ↗ | GlobeNewswire Inc. | Oct 15, 2026 | bullish | 1 | 1 |
| Natera Gains 118.1% in a Year: What's Driving the Rally? - TradingView | Natera Gains 118.1% in a Year: What's Driving the Rally? TradingView | View source ↗ | TradingView | Oct 15, 2026 | neutral | 0 | 0.6 |
| Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now? | PBE is a smart beta ETF focused on biotechnology and genome companies with $412.99 million in assets. It has delivered strong year-to-date returns of 16.68% and one-year returns of 36.23%, but carries higher risk with a standard deviation of 20.18%. The fund charges a 0.59% expense ratio and holds concentrated positions in healthcare stocks like Natera, Illumina, and Biogen. Cheaper alternatives like XBI and IBB are available for investors seeking lower-cost options. | View source ↗ | Zacks Investment Research | Oct 14, 2026 | bullish | 0.5 | 1 |
| Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now? | PBE is a smart beta ETF focused on biotechnology and genome companies with $412.99 million in assets. It has delivered strong year-to-date returns of 16.68% and one-year returns of 36.23%, but carries higher risk with a standard deviation of 20.18%. The fund charges a 0.59% expense ratio and holds concentrated positions in healthcare stocks like Natera, Illumina, and Biogen. Cheaper alternatives like XBI and IBB are available for investors seeking lower-cost options. | View source ↗ | Zacks Investment Research | Oct 14, 2026 | bullish | 0.5 | 1 |
| No approved treatment exists for colorectal cancer patients with cancer signals but clear scans. A trial will test one. - Stock Titan | No approved treatment exists for colorectal cancer patients with cancer signals but clear scans. A trial will test one. Stock Titan | View source ↗ | Stock Titan | Oct 13, 2026 | neutral | 0 | 0.6 |
| Tempus AI Expands Strategic Collaborations to Drive Future Growth | Tempus AI (TEM) is strengthening its precision medicine presence through multiple strategic collaborations, including support for Moderna and Merck's cancer therapy commercialization and an extended data partnership with Recursion Pharmaceuticals through 2029. However, TEM's stock has underperformed the industry by 30.6% over the past year and trades at a premium valuation of 6.73X forward P/S versus the industry average of 4.90X, with the stock currently rated a Hold. | View source ↗ | Zacks Investment Research | Oct 12, 2026 | bullish | 0.833 | 1 |
| Natera (NTRA) Stock May Be 33% Below Fair Value Despite FDA Breakthrough News - Yahoo Finance | Natera (NTRA) Stock May Be 33% Below Fair Value Despite FDA Breakthrough News Yahoo Finance | View source ↗ | Yahoo Finance | Oct 10, 2026 | neutral | 0 | 0.6 |
| Why Natera (NTRA) Stock Is Up Today - Yahoo Finance | Why Natera (NTRA) Stock Is Up Today Yahoo Finance | View source ↗ | Yahoo Finance | Oct 10, 2026 | neutral | 0 | 0.6 |
| Natera Stock Price Forecast. Should You Buy NTRA? - StockInvest.us | Natera Stock Price Forecast. Should You Buy NTRA? StockInvest.us | View source ↗ | StockInvest.us | Oct 9, 2026 | neutral | 0 | 0.6 |
| Why Natera (NTRA) Stock Is Up Today - The Globe and Mail | Why Natera (NTRA) Stock Is Up Today The Globe and Mail | View source ↗ | The Globe and Mail | Oct 9, 2026 | neutral | 0 | 0.6 |
| A blood test for multiple cancers gets FDA breakthrough designation - Stock Titan | A blood test for multiple cancers gets FDA breakthrough designation Stock Titan | View source ↗ | Stock Titan | Oct 9, 2026 | neutral | 0 | 0.6 |
| Natera: Priced To Perfection Amidst Rising Competitive Threats (NASDAQ:NTRA) - Seeking Alpha | Natera: Priced To Perfection Amidst Rising Competitive Threats (NASDAQ:NTRA) Seeking Alpha | View source ↗ | Seeking Alpha | Oct 7, 2026 | neutral | 0 | 0.6 |
| Natera (NasdaqGS:NTRA) Stock Forecast & Analyst Predictions - Simply Wall Street | Natera (NasdaqGS:NTRA) Stock Forecast & Analyst Predictions Simply Wall Street | View source ↗ | Simply Wall Street | Oct 7, 2026 | neutral | 0 | 0.6 |
| Natera Inc Stock (NTRA) Moved Down by 5.30% on Oct 6: A Full Analysis - TradingKey | Natera Inc Stock (NTRA) Moved Down by 5.30% on Oct 6: A Full Analysis TradingKey | View source ↗ | TradingKey | Oct 6, 2026 | neutral | 0 | 0.6 |
| Natera director Sheena’s trusts dispose of $7.0m in NTRA stock - Investing.com | Natera director Sheena’s trusts dispose of $7.0m in NTRA stock Investing.com | View source ↗ | Investing.com | Sep 25, 2026 | neutral | 0 | 0.6 |
| Why Is Natera (NTRA) Stock Soaring Today - StockStory | Why Is Natera (NTRA) Stock Soaring Today StockStory | View source ↗ | StockStory | Sep 22, 2026 | neutral | 0 | 0.6 |
| NTRA Stock Hits All-Time High, OMER Stock Scales 5-Year Peak – What’s Driving Investors’ Enthusiasm Today? - Stocktwits | NTRA Stock Hits All-Time High, OMER Stock Scales 5-Year Peak – What’s Driving Investors’ Enthusiasm Today? Stocktwits | View source ↗ | Stocktwits | Sep 22, 2026 | neutral | 0 | 0.6 |
| Natera (NTRA) Stock Fair Value Rises After Signatera And Guidance Drive Analyst Revisions - Yahoo Finance | Natera (NTRA) Stock Fair Value Rises After Signatera And Guidance Drive Analyst Revisions Yahoo Finance | View source ↗ | Yahoo Finance | Sep 19, 2026 | neutral | 0 | 0.6 |
| Natera: Even 30% Annual Growth Through 2030 Doesn't Support $310 Per Share (NASDAQ:NTRA) - Seeking Alpha | Natera: Even 30% Annual Growth Through 2030 Doesn't Support $310 Per Share (NASDAQ:NTRA) Seeking Alpha | View source ↗ | Seeking Alpha | Aug 20, 2026 | neutral | 0 | 0.6 |
| Why Natera (NTRA) Stock Rose Today - Quiver Quantitative | Why Natera (NTRA) Stock Rose Today Quiver Quantitative | View source ↗ | Quiver Quantitative | Aug 6, 2026 | neutral | 0 | 0.6 |
| Why Natera (NTRA) Stock Is Up Today - StockStory | Why Natera (NTRA) Stock Is Up Today StockStory | View source ↗ | StockStory | Jun 24, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.